ARTICLE | Company News
EMA reviewing Durata's dalbavancin
December 24, 2013 12:12 AM UTC
EMA accepted for review an MAA from Durata Therapeutics Inc. (NASDAQ:DRTX) for dalbavancin ( RQ-00000002) to treat complicated skin and soft tissue infections (cSSTI) caused by susceptible Gram-positi...